WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq: INCY) today announced that eleven abstracts detailing its emerging development pipeline will be presented at the 2015 American Association for Cancer Research (AACR) Annual Meeting in Philadelphia, PA. These abstracts include characterizations of Incyte’s FGFR, BRD and PIM inhibitors as potential targeted therapies for cancer, as well as data supporting the potential immuno-therapeutic activity of the company’s portfolio of JAK and PI3Kd inhibitors alone and in combination, including with epacadostat, Incyte’s leading IDO1 inhibitor.
Help employers find you! Check out all the jobs and post your resume.
